Overview

The U.S. Food and Drug Administration (FDA) is one of the 11 operating divisions within the United States Department of Health and Human Services (HHS). It ensures “the safety and efficacy of human and veterinary drugs, biologic products, and medical devices,” along with ensuring the safety of the food supply chain, cosmetics, and devices that emit radiation, that are marketed or sold in the U.S. The FDA also has responsibility for the regulation of tobacco products. It carries out this authority by reviewing manufacturers’ applications to sell these items in the United States. The FDA does not consider price in its approval process, nor is the agency involved in setting prices for any medical product on the market. However, FDA approvals come with market exclusivity periods which are closely tied with how drugs are priced (you can learn more about drug pricing in this Handbook’s Chapter 5).

The FDA balances pressures from multiple constituencies – to make products available in a timely manner, but also to ensure that they are safe and
efficacious if used as indicated. The agency is under constant pressure to ensure that critical innovations (such as COVID-19 vaccines) are available to the public as expeditiously as possible. Of course, it is impossible to know whether an innovation is important before subjecting it to the very testing that can delay its availability. To carry out its work of determining whether products are safe and efficacious for the public, the agency relies, to a significant extent, on funding provided in the form of user fees paid by those products’ producers.

### Background

The federal role in regulating food and drugs dates back to the nineteenth century. The predecessor to the Food and Drug Administration was the Bureau of Chemistry, created within the Department of Agriculture in 1862. The bureau was given its first modern regulatory functions over the pharmaceutical market in the 1902 Biologics Control Act and the 1906 Pure Food and Drugs Act. In 1927, the bureau

<table>
<thead>
<tr>
<th>Table 4.1: Definitions of Drugs, Including Biological Therapeutics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type of Drug or Therapy</strong></td>
</tr>
<tr>
<td>Innovator or Originator Drugs</td>
</tr>
<tr>
<td>Generic Drugs</td>
</tr>
<tr>
<td>Biologic</td>
</tr>
<tr>
<td>Biosimilar</td>
</tr>
<tr>
<td>Gene Therapies</td>
</tr>
<tr>
<td>Cell Therapies</td>
</tr>
<tr>
<td>Specialty Drugs</td>
</tr>
</tbody>
</table>
was reorganized and its regulatory entity became the Food and Drug Administration. The Food, Drug, and Cosmetic Act of 1938, for the first time, required drug manufacturers to submit safety data to the FDA for evaluation. The agency started evaluating for efficacy in 1962. Currently, the agency is organized into seven centers and 13 offices.

The term “drug” encompasses a wide range of substances used to diagnose, cure, mitigate, treat, or prevent disease. The term includes small molecule drugs and therapeutic biological products, which payers may cover under different benefits. Different types of drugs have different approval processes, distinct market characteristics, and face different pricing and cost challenges. Table 4.1 provides some basic definitions for various drugs and therapeutic biological products.

### Four Stages of a New Drug Review Process

The FDA reviews every drug and device that is marketed in America. The process for an innovator (or new) drug requires the manufacturer to go through four stages to prove the drug’s safety and efficacy (See Fig. 4.1).

In the first stage of the drug approval process, a drug sponsor develops a new molecular entity and then begins pre-clinical development. The process is likely to include initial testing on animals. The sponsor must then submit to the FDA an Investigational New Drug (IND) application before it can move to clinical trials on humans. The IND proposes a plan for evaluating the drug and a summary of the preclinical data collected to that point. Human clinical testing can start 30 days after IND submission unless the FDA objects and imposes a clinical hold.

In the second stage, the sponsor engages in clinical trials. In the first phase of clinical trials, the sponsor will work with a small group of individuals, often a dozen or so healthy volunteers, to test how the drug is absorbed, metabolized, and affects the body (i.e., pharmacokinetics and pharmacodynamics). In the second phase, the sponsor works with a larger group of volunteers, perhaps up to a hundred or so patients with the disease in question, to test the drug for safety and perhaps provide the first hint of efficacy. In the third phase, which is not mandatory, the sponsor will expand to an even larger group of patients, hundreds or even thousands of individuals, to test the drug’s efficacy compared to a placebo or other standards of care. The sponsor continues to gather safety data as well.

### Fig 4.1 Drug Development and FDA Marketing Approval Process Steps

<table>
<thead>
<tr>
<th>Drug Discovery</th>
<th>Pre-Clinical</th>
<th>Clinical Trials</th>
<th>FDA Marketing Application Review and Approval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research for a new drug begins in the laboratory.</td>
<td>Drugs undergo laboratory and animal testing to answer basic questions about safety.</td>
<td>Drugs tested for safety and efficacy.</td>
<td>Marketing application submitted to FDA.</td>
</tr>
<tr>
<td><img src="image1" alt="Microscope" /></td>
<td><img src="image2" alt="Rats" /></td>
<td><img src="image3" alt="People" /></td>
<td><img src="image4" alt="File" /></td>
</tr>
<tr>
<td><img src="image5" alt="FDA" /></td>
<td><img src="image6" alt="FDA" /></td>
<td><img src="image7" alt="FDA" /></td>
<td><img src="image8" alt="FDA" /></td>
</tr>
</tbody>
</table>

FDA either approves or does not approve the drug for marketing.

In the third stage, the drug sponsor submits a New Drug Application (NDA) to the FDA. The NDA is the sponsor’s formal request to have the FDA approve the drug for marketing and distribution in the United States. FDA scientists review the NDA inclusive of all the data collected by the sponsor from its use anywhere in the world, and approve the drug’s manufacturer-written labeling that summarizes all of that data. The FDA also inspects the facilities where the drug will be manufactured. When all of these separate steps have been concluded to the FDA’s satisfaction, the drug is approved for sale in the U.S. market for a particular disease or indication.

In the fourth stage, the FDA continues to work with the drug sponsor to monitor the drug for side effects that may occur while on the market (also known as post-market surveillance). Prescribers and consumers can bring any adverse events that occur with the use of the drug to the FDA’s attention. If evidence emerges that an approved drug is safe and effective for additional clinical uses, manufacturers can submit a streamlined application (“efficacy supplements”).

This streamlined approval is not to be confused with off-label uses, i.e., unapproved uses for an approved drug.

### Generic Drug Review Process

**Generic drugs** do not have to go through the extensive efficacy and safety trials expected of the innovator drug. A generic drug goes through an *Abbreviated New Drug Application* process in which the generic sponsor is required to prove that the generic drug is bioequivalent to the innovator drug. If the generic sponsor can meet that benchmark, it does not have to conduct costly and duplicative clinical trials to establish the generic drug’s safety and efficacy. This abbreviated process allows generic drugs to come to the market faster. Generic drugs are usually cheaper because there are typically multiple generic manufacturers, and FDA-approved generic drugs are generally automatically interchangeable at the pharmacy level for their brand-name drugs (see chapter 5 of the Handbook for more details).

### Biologic and Biosimilar Drug Review Process

Unlike chemically synthesized drugs, **biologic** drugs are complex combinations of sugars, proteins, or nucleic acids that are usually produced by living cells and tissues. Innovator biologics require an approval process called *Biologics License Application* (BLA) that mirrors the NDA process. **Biosimilar** drugs are meant to replicate an existing biologic drug’s clinical outcome and therefore go through a more extensive review process than generic drugs. The goal of the approval process is to show that the biosimilar drug has a similar structure to a reference innovator drug and can be expected to have no clinical differences.
Device Review Process

The FDA has broad authority over any device used in the care of a person or animal. While a popsicle stick and a tongue depressor may look like similar pieces of wood, only a tongue depressor is considered a device under the FDA's authority because it is intended to be used for clinical purposes.

The FDA divides medical devices into three classes and the approval process for each varies depending on the assigned class of the device in question. **Class I** devices (tongue depressors) pose the lowest risk to the patient and are simply registered with the FDA without any formal review. **Class II** devices pose a moderate risk and require clearance from the FDA. Most Class II devices reach the market by submitting a 510(k) application that shows they are substantially equivalent to another already legally marketed device. **Class III** devices have the greatest potential risk to the patient, and new Class III devices require premarket approval from the FDA, going through a process similar to those for new drugs or biologics.

New technologies have made the device field even more complex in recent years, especially when a device is used in combination with a drug or biologic. Software, for example, has historically been excluded from the FDA’s approval process as a medical device. However, software that is diagnostic and is connected to a hardware medical device is subject to the approval process. As artificial intelligence and machine learning advance, the FDA’s challenge in determining what is and is not a medical device will only grow more complicated.

Expedited Approval and Emergency Use Authorizations

The FDA has the authority to expedite the development and review process for drugs, biologics, and devices deemed to fill an unmet medical need or offer better health outcomes. There are four mechanisms that alter the process – fast track and breakthrough product designations change the administrative procedures of the review, accelerated approval designation modifies the clinical evidence needed in an application, and priority review designation accelerates the FDA application review start date. Additionally, in public health emergency situations, the Secretary of Health and Human Services and FDA may utilize **Emergency Use Authorization** (EUA) to permit the use of unapproved medical products or unapproved uses of approved medical products to provide medical countermeasures. Recent issuances of EUAs were in December 2020 and February 2021 to allow use of vaccines against COVID-19.

As artificial intelligence and machine learning advance, the FDA’s challenge in determining what is and is not a medical device will only grow more complicated.
The FDA oversees dietary supplements like it does foods; however, there is no approval process requiring dietary supplements to show efficacy or safety. One of the FDA’s roles is to ensure that a dietary supplement’s intended effect is not misrepresented to the public.

What the FDA Does Not Do

The FDA is statutorily charged with approving products under its jurisdiction if they are (1) safe and efficacious when used as indicated and (2) if their benefits outweigh their risks. The FDA does not engage in any effort to evaluate comparative effectiveness between any two drugs or devices. The FDA does not have the authority to require product sponsors to show comparative effectiveness with other products that treat the same condition. However, most clinical trials treat their control group with the current standard of care. The agency also does not oversee the practice of medicine and pharmacy — which are state-based and govern how medicines are used in practice.

The FDA also does not consider the pricing of any drug or device as part of its review process, and subsequently most products going through FDA review do not have a price attached as they are yet to be approved for marketing in the U.S.

The FDA does not determine whether a drug or device will be covered by insurance or other payers. The FDA approves a drug or device for use by the public for a specific indication, although physicians may prescribe off-label for additional disease or conditions as they are covered by state-based medical licenses and the practice of medicine. Payers determine whether to cover a drug or device within the terms of their insurance programs. While FDA approval makes coverage highly likely for private insurers, it is not a certainty, and coverage can vary depending on the availability of multiple medicines, including generics, for any given condition. However, FDA approval generally guarantees coverage by Medicaid (if manufacturers choose to participate), and specific categories of drugs are also required to be covered by Medicare Part D plans. For drugs not subject to guaranteed Medicare coverage, Part D plans have their own review processes for determining if an approved drug or device should be covered.

GLOSSARY OF TERMS

Patent: Granted by the U.S. Patent and Trademark Office and provides for the protection of property rights, for example, in the active ingredient of a drug. The term of the patent is 20 years from the date of application.

Exclusivity: Prohibits the approval of competitor drugs by the FDA. All new drugs get five years of exclusivity from their FDA approval date. However, different types of exclusivities are intended to provide additional incentives for the production of certain types of drugs.

Safety: “Often measured by toxicity testing to determine the highest tolerable dose or the optimal dose of a drug needed to achieve the desired benefit.” A safe drug does not mean that there are no side effects, but benefits outweigh the potential risks of side effects and that the drug is not toxic. Safety trials may also identify adverse events (injury resulting from medical intervention).

Efficacy: Performance of an intervention under ideal and controlled circumstances.

Effectiveness: Performance of an intervention under real-world conditions.
User Fee Acts

In 1992, Congress passed the first Prescription Drug User Fee Act (PDUFA), in part, as a response to drug manufacturer and patient advocate complaints about delays in the FDA approval process. The act’s solution was to require manufacturers to pay a user fee at the time of the NDA submission, which the FDA then used to increase staffing to address pending applications.

The User Fee Act’s purview for originator drugs has since been expanded to include user fees for animal drugs, generic drugs, biosimilars, and medical devices. The whole Act (and its amendments for other drug/device types) is subject to renewal every five years. The process of writing the legislation to extend the act is carefully negotiated between the industry and the FDA, with results presented to Congress for approval. Through the negotiations, each of the parties, as well as stakeholder groups like patient advocates, are trying to achieve improvements they see as being in their interests.

Patents v. Exclusivity and the Hatch-Waxman Act

Patents and exclusivity are similar in concept in that they relate to how long a new drug can be on the market before the drug can be replicated and sold by competitors. Still, they are distinct and governed by different statutes and parts of the government. A patent is granted by the U.S. Patent and Trademark Office and provides for the protection of property rights, for example, the active ingredient of a drug. The term of the patent is 20 years from the date of application, regardless of the drug’s FDA approval status.

Exclusivity prohibits the approval of competitor drugs by the FDA. All new drugs get five years exclusivity from their date of approval by the FDA. However, there are different types of exclusivities intended to provide supplemental incentives for the production of certain types of drugs. For instance, drugs for rare diseases (sometimes called orphan drugs) receive an exclusivity of seven years, and drugs tested in children receive an additional six months added to their existing exclusivity. Additional exclusivities may be limited to an individual indication rather than the entire product.

The first generic drug to the marketplace can earn a 180-day period of exclusivity from other generic entrants, which encourages generic manufacturers to challenge brand-name manufacturers’ patents so they may be the first to bring competition to the market. Patent terms and exclusivity periods may or may not co-occur.

Many of these provisions were initially established in the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, which intended to preserve the incentives that bring innovator drugs to the market while allowing a streamlined process for the approval of generic drugs. The Act provided for patent extensions to account for clinical testing and regulatory review periods and minimum competition-free periods for drugs without patents. In addition, a streamlined process was formalized to bring generic competition to the market after the exclusivity period. The FDA publishes a compendium of approved drugs with therapeutic equivalents (generics), commonly referred to as the Orange Book (for the orange cover from its original printing). The Orange Book lists key patent and exclusivity information for drugs approved by the FDA.

In theory, patent terms and exclusivity periods reward innovators for bringing new drugs to the market by allowing them to charge monopoly prices while preventing competitors from immediately copying their products. When the exclusivity period expires, competition from generic drugs benefits consumers by bringing down the cost of prescription drugs. Patent-related protection from generic competition can often extend past 20 years because brand-name manufacturers may obtain numerous patents on multiple aspects of their drug, including its formulation, salt forms, and uses (method patents).

Chapter 5 of this Handbook goes into more detail about the many facets and actors that impact the final cost and price of prescription drugs, as well as the various financing challenges and opportunities.

This Handbook was organized by the Alliance for Health Policy in partnership with Health Affairs, and made possible with generous support from Arnold Ventures.
RESOURCES
Chapter 4: U.S. Food & Drug Administration
Listed by the order in which they appear in Chapter 4.

OVERVIEW
HHS Organizational Chart. http://allh.us/WKPh
What Does FDA Regulate? http://allh.us/hpwJ
The Food and Drug Administration (FDA) Budget: Fact Sheet. http://allh.us/6fcK
FDA User Fee Programs. http://allh.us/Yafe

BACKGROUND
When and Why Was FDA formed? http://allh.us/79wk
FDA History. http://allh.us/vWq7
FDA Overview Organization Chart. http://allh.us/r6RK
Drugs@FDA Glossary of Terms. http://allh.us/eF9D

FOUR STAGES OF A NEW DRUG REVIEW PROCESS
The FDA's Drug Review Process: Ensuring Drugs Are Safe and Effective. http://allh.us/7mDA
How FDA Approves Drugs and Regulates Their Safety and Effectiveness. http://allh.us/7DKG
What is a Serious Adverse Event? http://allh.us/vjhu
New and Expanded Uses of Already FDA-Approved Drugs. http://allh.us/PaDc
Understanding Unapproved Use of Approved Drugs "Off Label". http://allh.us/gM9m

GENERIC DRUG REVIEW PROCESS
Abbreviated New Drug Application (ANDA). http://allh.us/TB8q

BIOLOGIC AND BIOSIMILAR DRUG REVIEW PROCESS
Development & Approval Process (CBER). http://allh.us/qc7D

DEVICE REVIEW PROCESS
Overview of Device Regulation. http://allh.us/KRHz

EXPEDITED APPROVAL AND EMERGENCY USE AUTHORIZATIONS
Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review. http://allh.us/EypF
How FDA Approves Drugs and Regulates Their Safety and Effectiveness. http://allh.us/yu6v
Emergency Use Authorization. http://allh.us/Kn9g

USER FEE ACTS
FDA User Fee Programs. http://allh.us/Yafe

PATENTS V. EXCLUSIVITY AND THE HATCH WAXMAN ACT

Table 4.1
Drugs@FDA Glossary of Terms. http://allh.us/IPF7
Biosimilars. http://allh.us/9QYA
Cellular & Gene Therapy Products. http://allh.us/kdyx
Congressional Research Service: Specialty Drugs – Background and Policy Concerns. http://allh.us/7MNh

Box: Key FDA Issues in 2021
Reauthorization of the Prescription Drug User Fee Act; Public Meeting; Request for Comments. http://allh.us/8WKv
Building Upon the Promise of 21st Century Cures: The Cures 2.0 Concept Paper. http://allh.us/PdTm

Box: Glossary of Terms
How FDA Approves Drugs and Regulates Their Safety and Effectiveness. http://allh.us/7DFG